Basis grants $3.55 million in new analysis awards, bringing annual complete funding awarded to $3.87 million
FOR IMMEDIATE RELEASE
NEW YORK, December 10, 2024
The Lung Most cancers Analysis Basis® (LCRF) is happy to announce its 2024 Scientific Grant Program awards, funding $3.55 million in new analysis, the biggest single-year funding in its historical past. This 12 months’s grant cycle contains awards within the following areas: LCRF Main-Edge Grant in Lung Most cancers, LCRF Analysis Grant on Early Detection and Pre-Neoplasia in Lung Most cancers, LCRF Analysis Grants on Understanding Resistance in Lung Most cancers, LCRF Minority Profession Improvement Award (CDA) for Lung Most cancers, and the IASLC-LCRF Crew Science Analysis Grant on the Subsequent Step within the Treatment of Oncogene-Pushed Lung Cancers. Earlier this 12 months, LCRF awarded the American Lung Most cancers Screening Initiative (ALCSI), led by Chi-Fu Jeffrey Yang, MD, of Massachusetts Basic Hospital, a $320,000 grant to conduct its “Plus One” screening initiative and analysis research.
LCRF awarded its grants for initiatives that exhibit profound promise to make a sustained and lasting influence on lung most cancers analysis and outcomes. These grants are made attainable by Analysis ALK+ve Lung Most cancers UK, the LRE Basis, and quite a few beneficiant donations from LCRF’s supporters.
“Every year, our Scientific Advisory Board and Analysis Advocates evaluate a whole bunch of submissions,” stated Colleen Conner Ziegler, Chair of LCRF’s Board of Administrators. “This ensures that LCRF is funding initiatives that can have the best influence on the lung most cancers group and enhance affected person outcomes, each within the quick and long run.”
“As a result of analysis is LCRF’s True North, we’re dedicated to supporting science that seeks options to lung most cancers’s most difficult points and unmet wants,” stated Kathryn O’Donnell, PhD, chair of LCRF’s Scientific Advisory Board and Affiliate Professor, Molecular Biology, UT Southwestern Medical Heart. “Funding probably the most revolutionary analysis will finally result in improved outcomes for sufferers with lung most cancers.”
By way of its Main Edge Analysis Grant in Lung Most cancers, LCRF funds revolutionary analysis centered on the prevention, analysis, therapy, and remedy of lung most cancers. This 12 months, LCRF will probably be funding two initiatives via this mechanism.
LCRF’s Analysis Grant on Early Detection and Pre-Neoplasia in Lung Most cancers is offered to an investigator whose mission facilitates or advances the understanding and characterization of pre-neoplasia or approaches for early detection in non-small cell and small cell lung most cancers.
The LCRF Analysis Grants on Understanding Resistance in Lung Most cancers are offered to 2 recipients whose initiatives concentrate on combatting therapeutic resistance.
LCRF’s Minority Profession Improvement Award for Lung Most cancers, a two-year award to assist early-stage scientists from underrepresented teams, is supported partly by a grant from the LRE Basis. This 12 months, LCRF will fund two initiatives on this space that can enhance the illustration of investigators from underrepresented teams within the lung most cancers analysis workforce.
In partnership with the Worldwide Affiliation for the Examine of Lung Most cancers (IASLC), the IASLC-LCRF Crew Science Analysis Grant on the Subsequent Step within the Treatment of Oncogene-Pushed Lung Cancers award, is a $2.5 million award over 4 years granted to a workforce of scientists whose coordinated initiatives advance analysis in oncogene-driven lung most cancers with the intent to culminate in a scientific trial.
Every year, LCRF acknowledges exemplary initiatives via its James B. Dougherty, MD Award for Scientific Benefit, and William C. Rippe Award for Distinguished Analysis in Lung Most cancers, in honor of the contributions to LCRF made by these esteemed former board members. This 12 months, LCRF added the Cynthia M. Web page Benefit Award in reminiscence of Ms. Web page, whose household established the LRE Basis and funded the grant awarded in her honor.
The James B. Dougherty, MD Award for Scientific Benefit is offered to the investigator whose proposal was chosen for excellent total advantage by the Basis’s Scientific Advisory Board. This 12 months’s recipient is Dian Yang, PhD of Columbia College Irving Medical Heart, whose mission is titled “Investigating the molecular foundation of most cancers plasticity in LKB1-mutant lung adenocarcinoma.”
“This LCRF Main Edge Analysis Grant will allow my lab to research the molecular mechanisms driving most cancers plasticity in Lkb1-mutant lung adenocarcinoma, shedding gentle on potential methods for growing revolutionary therapies,” remarked Dr. Yang.
LCRF’s William C. Rippe Award for Distinguished Analysis in Lung Most cancers is offered to the investigator whose proposal not solely demonstrated distinctive scientific advantage but additionally exemplified a permanent dedication to creating an influence within the area of lung most cancers analysis. This 12 months’s recipient is Lindsay LaFave, PhD of Albert Einstein School of Drugs, whose mission is titled “Investigating chromatin-mediated mechanisms of immune response in lung most cancers.”
“I’m honored to obtain the William C. Rippe Award for Distinguished Analysis in Lung Most cancers from the Lung Most cancers Analysis Basis,” stated Dr. LaFave. “Due to the assist from LCRF we hope to raised perceive variations in immunity in people with and with no smoking historical past to enhance immunotherapy outcomes in lung most cancers.”
The Cynthia M. Web page Benefit Award for Innovation in Lung Most cancers Analysis is awarded to the investigator whose proposal demonstrates distinctive scientific advantage and groundbreaking innovation, pushing the boundaries of lung most cancers analysis with artistic, forward-thinking approaches. Tikvah Hayes, PhD, of the David Geffen Faculty of Drugs at UCLA is the recipient of this award. Dr. Hayes’s mission is titled “Advancing preclinical cell line range and decoding TKI-resistance landscapes in EGFR-mutant lung most cancers.”
“Thanks to LCRF and the LRE Basis for this meritorious award,” remarked Dr. Hayes. “I’m hopeful that we’ll develop revolutionary fashions and instruments to evaluate the underlying biology of EGFR-mutant lung cancers.”
The IASLC – LCRF Crew Science Analysis Grant on the Subsequent Step within the Treatment of Oncogene-Pushed Lung Cancers, introduced final month, was awarded to a world workforce led by David A. Barbie, MD, Director of the Lowe Heart for Thoracic Oncology at Dana-Farber Most cancers Institute, together with Aaron Hata, MD, PhD of Massachusetts Basic Hospital; Eric Smith, MD, PhD of Dana-Farber Most cancers Institute; Pasi Jänne, MD, PhD of Dana-Farber Most cancers Institute; and Shunsuke Kitajima, PhD representing the Japanese Basis for Most cancers Analysis. Their mission is titled, “Immune elimination of drug tolerant persister cells in oncogene-driven lung most cancers.”
LCRF 2024 Analysis Grant Awardees
Main Edge Grant Program
Lindsay LaFave, PhD, Albert Einstein School of Drugs
William C. Rippe Award for Distinguished Analysis in Lung Most cancers recipient
Investigating chromatin-mediated mechanisms of immune response in lung most cancers
Dian Yang, PhD, Columbia College Irving Medical Heart
James B. Dougherty, MD Award for Scientific Benefit recipient
Investigating the molecular foundation of most cancers plasticity in LKB1-mutant lung adenocarcinoma
Minority Profession Improvement Award (CDA)
Tikvah Hayes, PhD, David Geffen Faculty of Drugs at UCLA
Cynthia M. Web page Benefit Award for Innovation in Lung Most cancers recipient
Advancing preclinical cell line range and decoding TKI-resistance landscapes in EGFR-mutant lung most cancers
Luisa Escobar-Hoyos, MSc, PhD, Yale College
Altered RNA splicing as a driver of Osimertinib resistance in lung most cancers
Analysis Grant on Early Detection and Pre-Neoplasia in Lung Most cancers
Peggy Hsu, MD, PhD, College of Michigan
Understanding the origin of ALK-driven lung most cancers
Analysis Grants on Understanding Resistance in Lung Most cancers
William Feng, PhD, Dana-Farber Most cancers Institute
Concentrating on AP-1 in KRAS-mutant lung most cancers
Megan Burger, PhD, Oregon Well being & Science College
Optimizing immunotherapy sequencing to beat resistance
IASLC-LCRF Crew Science Analysis Grant on the Subsequent Step within the Treatment of Oncogene-Pushed Lung Cancers
David A. Barbie, MD, Dana-Farber Most cancers Institute
Aaron Hata, MD, PhD, Massachusetts Basic Hospital – Harvard Medical Faculty
Pasi Jänne, MD, PhD, Dana-Farber Most cancers Institute – Harvard College
Shunsuke Kitajima, PhD, the Japanese Basis for Most cancers Analysis
Eric Smith, MD, PhD, Dana-Farber Most cancers Institute – Harvard College
Immune elimination of drug tolerant persister cells in oncogene-driven lung most cancers
For extra details about LCRF and the Scientific Grant Program, go to LCRF.org/analysis.
###
In regards to the Lung Most cancers Analysis Basis
The Lung Most cancers Analysis Basis® (LCRF) is the main nonprofit group centered on funding revolutionary, high-reward analysis with the potential to increase survival and enhance high quality of life for individuals with lung most cancers. LCRF’s mission is to enhance lung most cancers outcomes by funding analysis for the prevention, analysis, therapy, and remedy of lung most cancers. Thus far, LCRF has funded 428 analysis grants, totaling almost $48 million, the best quantity offered by a nonprofit group devoted to funding lung most cancers analysis. For extra details about the LCRF grant program and funding alternatives, go to LCRF.org/analysis.
Contact:
Sheila Sullivan
Sr. Director, Advertising and Communications
ssullivan@lcrf.org